Wilmington PharmaTech Plans New R&D-Manufacturing Complex in Newark, Delaware

Wilmington PharmaTech will invest $18 million on a new state-of-the-science research and manufacturing facility in Newark, Delaware. The company plans to hire up to 139 new associates.
A Contract Research/Manufacturing Organization, Wilmington PharmaTech provides integrated services to pharmaceutical companies and biotech firms to expedite new pharmaceutical product development. One of their main offerings is the manufacturing of Active Pharmaceutical Ingredients and related materials under cGMP, which is an important aspect in the drug development process that is required to ensure product quality and provide consistency during formulation and manufacture.